WHAT IS CLAIMED IS:

1. Use of at least one PD-1 and/or PD-L1 antagonist in the manufacture of a medicament for treating cancer in a patient, wherein the patient is to be administered with at least one dose of radiation therapy,

    wherein the medicament is to be administered on the same day as a dose of radiation therapy or up to and including 4 days later.

2. The use according to claim 1, wherein the at least one PD-1 and/or PD-L1 antagonist is an at least one PD-1 and/or PD-L1 antibody or functional part thereof.

3. The use according to claim 1, wherein the dose of radiation therapy is about 70 Gy or lower.

4. The use according to claim 3, wherein the dose of radiation therapy is about 50 Gy or lower.

5. The use according to claim 4, wherein the radiation therapy is fractionated radiation therapy.

6. The use according to claim 5, wherein the fractionated radiation therapy comprises from 2 to 7 fractions.

7. The use according to claim 6, wherein the fractionated radiation therapy comprises 5 fractions.

8. The use according to claim 7, wherein the radiation therapy fractions are to be administered in sequential days.

9. The use according to claim 8, wherein the radiation therapy fractions are to be administered on day 1, day 2, day 3, day 4, and day 5.

10. The use according to claim 9, wherein the radiation therapy comprises about 70 Gy in 5 fractions.

11. The use according to claim 1, wherein the medicament is to be administered on day 1.

12. The use according to claim 1, wherein the medicament is to be administered on day 5.

13. The use according to claim 1, wherein the medicament is to be administered multiple times.

14. The use according to claim 13, wherein the medicament is to be administered 3 times a week.

15. The use according to claim 14, wherein the anti-PD-1 and/or PD-L1 antibody or functional part thereof is MEDI4736.

16. The use according to claim 15, wherein the anti-PD-1 and/or anti-PD-L1 antibody or functional part thereof is pembrolizumab, nivolumab, BMS-936558, AMP-224, or MPDL3280A.

17. The use according to claim 1, wherein the cancer is melanoma, colorectal cancer, or breast cancer.

18. The use according to claim 1, wherein more than one treatment cycle is to be performed.

19. The use according to claim 18, wherein from 2-8 treatment cycles are to be performed.

20. The use according to claim 19, wherein the treatment cycles to be performed are weekly or every other week.